Leading supplier of immunodiagnostic reagents BBI Solutions (BBI) has announced the launch of a full range of molecular tag gold conjugates.
Developed using BBI’s 40nm gold colloid under their ISO13485 certification, the new range incorporates antibodies against the most commonly used primer tags.
The full range includes Goat anti-biotin, Monoclonal anti-biotin, Monoclonal anti-FITC, Monoclonal anti-HRP, Monoclonal anti-his tag and Monoclonal anti-digoxin 40nm gold conjugates..
The molecular tag conjugates are suitable for use in lateral flow devices, in addition to biosensors, enabling the development of more molecular based testing at the point of care with a sensitivity similar to that which can be achieved by laboratory-based polymerase chain reaction (PCR) tests.
Dr Mario Gualano, CEO of The BBI Group, said: “The launch of our full molecular tag conjugate range strengthens our services for in vitro diagnostics manufacturers, particularly those looking to move molecular testing into the Point of care field.
“Like our wider portfolio, this range has been manufactured by our dedicated team of experienced conjugation scientists. Our long established, scalable conjugation process allows large scale manufacture and our range of conjugates offers flexibility to developers in both primer and assay design, providing exciting opportunities for point of care applications.”
BBI Solutions is trusted partner for thousands of researchers, lateral flow assay developers and manufacturers worldwide, BBI has over 30 years of experience manufacturing gold conjugates and nanoparticles.
Specialists in the development and manufacture of lateral flow assays, BBI also uses its capabilities in mobile health to provide a unique digital diagnostic platform. BBI’s patented Novarum™️ technology transforms a smartphone into a diagnostics test reader, empowering users to read, share and store their results from the point of care.
To review our new molecular tag conjugates and request a sample click below
| Request a sample |
About
BBI Solutions has been serving the global diagnostics industry for over 50 years and is the world’s largest independent producer of immunodiagnostics reagents.
BBI develops and manufactures critical components for the diagnostic industry and applies expertise by delivering solutions that bring critical components together in the development and manufacture of point of care and conventional tests.
BBI’s Novarum mobile diagnostic platform complements across the diagnostics workflow to interpret and share assay results, making BBI unique among IVD suppliers.
BBI’s range of immuno-diagnostics reagents includes human antigens, antibodies, enzymes and serum & plasma products.
BBI has manufacturing sites spanning four continents, producing world-renowned labels for lateral flow, ELISA assay and biosensors, including high-quality gold nanoparticles and glucose oxidase.
The acquisition of German-based DIARECT AG in June 2020 established BBI as the leading provider of antigens in the autoimmune and tick-borne IVD markets.
BBI Solutions is part of the BBI Group.
Website: www.bbisolutions.com
E-mail: info@bbisolutions.com
Tel: +44 (0) 1495 363 000
Media Contact
Laura Baker
T: +44 (0) 7876 824 248
